Translucence Co-Founders Damian Wheeler, Ph.D. and Sunil Gandhi, Ph.D. along with their colleagues Chase Redd and Nathaniel Guanzon recently presented at the Alzheimer's Association International Conference® 2022. To help move AD drug discovery forward, Translucence has developed whole-brain regional assays for β-Amyloid plaques and microglia and with Lundbeck, methods to measure antibody therapeutics crossing the Blood-Brain Barrier and homing in on their target.
Access the "Brain Wide Monitoring of Antibody Therapeutics Crossing the Blood/Brain Barrier" poster here.
![](https://cdn.prod.website-files.com/60ba1dd74b584159e3111e51/62fd7257ee05060d573de6b4_AAIC-2022-Lundbeck-poster-preview-2022-07-25a.jpg)
Access the "Brain-Wide Cellular Resolution Regional Quantification of Microglia and Amyloid in 5xfad Mice" poster here.
![](https://cdn.prod.website-files.com/60ba1dd74b584159e3111e51/62fff6167b46cd0c6bcd693a_AAIC-2022-AandM-poster-preview-2022-07-25a.jpg)
Ask your question
Send us your questions and we will get back to you as soon as possible
info@translucencebio.com